{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T04:17:25Z","timestamp":1729311445220,"version":"3.27.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clon.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:57:07Z","timestamp":1714179427000},"page":"710-718","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma"],"prefix":"10.1016","volume":"36","author":[{"given":"K.","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2024.04.010_bib1","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2020.02.183","article-title":"Development of a deep learning model for classifying thymoma as Masaoka-Koga stage I or II via preoperative CT images","volume":"8","author":"Yang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clon.2024.04.010_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"Margaritora","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clon.2024.04.010_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2019.09.015","article-title":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","volume":"137","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejcts.2010.09.042","article-title":"Thymoma: inter-relationships among World Health Organization histology, Masaoka staging and myasthenia gravis and their independent prognostic significance: a single-centre experience","volume":"40","author":"Ruffini","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.clon.2024.04.010_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/0003-4975(91)90999-7","article-title":"Role of staging in prognosis and management of thymoma","volume":"51","author":"Wilkins","year":"1991","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clon.2024.04.010_bib9","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1002\/cam4.3385","article-title":"Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma","volume":"9","author":"Okuma","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clon.2024.04.010_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2019.10.016","article-title":"Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203","volume":"139","author":"Tsukita","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A\u00a0phase II study of Pemetrexed in patients with recurrent thymoma and thymic carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib12","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the somach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib14","first-page":"693","article-title":"Apatinib treatment in extensive metastatic advanced thymic carcinoma","volume":"32","author":"He","year":"2018","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clon.2024.04.010_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12916-022-02361-w","article-title":"Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.clon.2024.04.010_bib16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/cam4.5053","article-title":"Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clon.2024.04.010_bib17","first-page":"1808","article-title":"Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma","volume":"6","author":"Song","year":"2014","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.clon.2024.04.010_bib18","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12094-022-02788-w","article-title":"SEOM-GECP-GETTHI clinical guidelines for the treatment of patients with thymic epithelial tumours (2021)","volume":"24","author":"Remon","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib20","first-page":"169","article-title":"Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinoma, Thorac","volume":"5","author":"Song","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-022-10448-z","article-title":"The efficacy of small molecule anti-angiogenic drugs in previously treated thymic carcinoma","volume":"23","author":"Guan","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2024.04.010_bib25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.04.010_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4143\/crt.2019.296","article-title":"Apatinib combined with local irradiation leads to systemic tumor control via reversal of immunosuppressive tumor microenvironment in lung cancer","volume":"52","author":"Liang","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.04.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108387","article-title":"Immunotherapy for hepatocellular carcinoma: recent advances and future targets","volume":"244","author":"Yu","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clon.2024.04.010_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.crimmu.2022.05.003","article-title":"Clinically approved combination immunotherapy: Current status, limitations, and future perspective","volume":"3","author":"Lu","year":"2022","journal-title":"Curr Res Immunol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T19:24:28Z","timestamp":1729279468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0936655524001705"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.04.010","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}